1
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
Condition(s):Non-small-cell Lung CancerLast Updated:May 13, 2022Completed
XL647 as an Intervention: 13 Clinical Trials, Page 1 of 2
Hide Studies Not Open or Pending
2
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
Condition(s):CancerLast Updated:May 13, 2022Completed
3
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:May 13, 2022Completed
4
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Condition(s):CancerLast Updated:May 13, 2022Completed
5
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Condition(s):Cancer; Non-small-cell Lung Cancer; Breast CancerLast Updated:August 20, 2015Withdrawn
6
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Condition(s):Polycystic Kidney, Autosomal DominantLast Updated:May 31, 2022Completed
7
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Condition(s):Glioblastoma; Recurrent Glioblastoma; Brain TumorLast Updated:September 22, 2021Completed
8
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Condition(s):Non-Small Cell Lung Cancer; Leptomeningeal Metastases; Brain MetastasesLast Updated:March 16, 2022Completed
9
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Condition(s):Autosomal Dominant Polycystic Kidney Disease (ADPKD)Last Updated:May 25, 2022Terminated
10
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Condition(s):HER-2 Positive Breast Cancer; Metastatic Malignant Neoplasm to BrainLast Updated:April 27, 2022Terminated